Alpha Profiles · Company Profile

Agomab Therapeutics NV

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies.

https://registry.alpha.ac/companies/agomab-therapeutics-nv

Entity: Public listing published
Primary listing: NASDAQ: AGMB
Verification: Partially verified
Last reviewed: 2026-09-14T14:36:31.481633+00:00

Overview

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to trea

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 14, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-09-14T14:36:31.481633+00:00